Erythrocyte alloantibody formation Laboratory assessment · women with postpartum iron deficiency anaemia
It is very uncertain whether red blood cell transfusion changes erythrocyte alloantibody formation Laboratory assessment compared with non‐transfusion (Comparison 2) (very low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Neurological adverse effects · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review
Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Mortality at latest · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Infection Number of participants diagnosed with infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in infection Number of participants diagnosed with infection compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
CMV infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Cancer · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cancer Number of participants diagnosed with cancer compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Mortality Mortality at latest · heart transplant recipients
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with polyclonal antibody induction (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA may leads to higher acute rejection Acute rejection grade 3A or more verified by biopsy compared with polyclonal antibody induction (low certainty).
1 finding from 1 review